Peter Olagunju - 15 Dec 2022 Form 4 Insider Report for TCR2 THERAPEUTICS INC.

Role: Chief Technical Officer
Signature: /s/ Margaret Siegel as Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 15 Dec 2022
Net transactions value: $0
Form type: 4
Filing time: 19 Dec 2022, 16:25:52 UTC
Previous filing: 13 Dec 2022
Next filing: 01 Jun 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	TCRR	Common Stock						24,092	15 Dec 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TCRR	Stock Option (Right to Buy)	Award	$0	+98,124		$0.000000	98,124	15 Dec 2022	Common Stock	98,124	$0.9700	Direct	F1
transaction	TCRR	Restricted Stock Unit (Right to Buy)	Award	$0	+16,354		$0.000000	16,354	15 Dec 2022	Common Stock	16,354		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	25% of this option shall vest and become exercisable on the one-year anniversary of the date of grant, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.
F2	Each restricted stock unit represents a right to receive one share of the issuer's common stock at the time of vesting for no consideration.
F3	The restricted stock units will vest 25% on the one-year anniversary of the date of grant, with the remainder vesting in three equal annual installments thereafter.